Not Yet RecruitingPhase 2/3

A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.

China914 participantsStarted 2026-07

Plain-language summary

The study is being conducted to evaluate the efficacy and safety of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension. To explore the optimal use of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension。

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Male or female, aged ≥ 18 and \< 80 years ；
. Mean trough seated SBP ≥ 140 mmHg and \< 170 mmHg at both screening and randomization visits.
. Meet one of the following two criteria:
. Meet the criteria for uncontrolled hypertension；
. Meet the criteria for resistant hypertension；
. Serum potassium ≥ 3.5 mmol/L and ≤ 5.0 mmol/L ；
. Voluntarily sign the ICF prior to the study；
. Have no plan for fertility from the time of signing the ICF until 4 weeks after the last dose.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change from baseline in trough seated SBP at Week 12

Timeframe: baseline and Week 12

Trial details

NCT IDNCT07708441

SponsorShandong Suncadia Medicine Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-04

Contact for this trial

Xue Dong

13511659605 xue.dong@hengrui.com

View on ClinicalTrials.gov More Uncontrolled or Resistant Hypertension trials

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Male or female, aged ≥ 18 and \< 80 years ；
. Mean trough seated SBP ≥ 140 mmHg and \< 170 mmHg at both screening and randomization visits.
. Meet one of the following two criteria:
. Meet the criteria for uncontrolled hypertension；
. Meet the criteria for resistant hypertension；
. Serum potassium ≥ 3.5 mmol/L and ≤ 5.0 mmol/L ；
. Voluntarily sign the ICF prior to the study；
. Have no plan for fertility from the time of signing the ICF until 4 weeks after the last dose.

A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Contact for this trial

A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Contact for this trial

Exclusion criteria